SCHEMBL1920349

SCHEMBL1920349

CCOC(=O)c1c(O)c2cnccc2n1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.49
KDM5A P29375 1/20 0.46
KDM5B Q9UGL1 1/20 0.46
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 3/20 0.46
MAPT P10636 2/20 0.44
GAA P10253 2/20 0.43
TSHR P16473 2/20 0.42
NPSR1 Q6W5P4 1/20 0.41
NPC1 O15118 1/20 0.40
ALOX15 P16050 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
ESR1 P03372 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
ESR2 Q92731 1/20 0.40
CA14 Q9ULX7 1/20 0.40
LMNA P02545 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1920371 0.85 MAPT (0.57) ELANEKDM5AKDM5BALDH1A1KDM4E
SCHEMBL9867870 0.80 ALDH1A1 (0.68) ELANEALDH1A1KDM4EMAPTGAA
SCHEMBL1920554 0.76 ALDH1A1 (0.43) ALDH1A1KDM4EMAPTGAACA12
SCHEMBL22346627 0.75 KDM4E (0.44) ELANEKDM5AKDM5BKDM4EMAPT
SCHEMBL22346601 0.75 KDM4E (0.53) ELANEKDM5AKDM5BALDH1A1KDM4E
SCHEMBL25942159 0.75 ELANE (0.49) ELANEKDM5AKDM5BALDH1A1KDM4E
SCHEMBL23145655 0.74 ELANE (0.56) ELANEKDM5AKDM5BTSHRNPSR1
SCHEMBL29811271 0.74 ELANE (0.56) ELANEKDM5AKDM5BTSHRNPSR1
SCHEMBL1920141 0.74 ELANE (0.39) ELANEKDM5AKDM5BALDH1A1KDM4E
SCHEMBL25942151 0.74 RAD52 (0.52) ELANEKDM5AKDM5BALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099796-B1 AZA-INDOLYL COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2011-06-01 EP disclosed
EP-2099796-B1 AZA-INDOLYL COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2011-06-01 EP disclosed
US-7855216-B2 Aza-indolyl compounds and methods of use GENENTECH, INC. (US) 2010-12-21 US disclosed
US-7855216-B2 Aza-indolyl compounds and methods of use GENENTECH, INC. (US) 2010-12-21 US disclosed
US-7855216-B2 Aza-indolyl compounds and methods of use GENENTECH, INC. (US) 2010-12-21 US disclosed
US-20080242655-A1 AZA-INDOLYL COMPOUNDS AND METHODS OF USE GENENTECH, INC. 2008-10-02 US disclosed
US-20080242655-A1 AZA-INDOLYL COMPOUNDS AND METHODS OF USE GENENTECH, INC. 2008-10-02 US disclosed
US-20080242655-A1 AZA-INDOLYL COMPOUNDS AND METHODS OF USE GENENTECH, INC. 2008-10-02 US disclosed
WO-2008067481-A1 AZA-INDOLYL COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242655-A1 AZA-INDOLYL COMPOUNDS AND METHODS OF USE CDKN1A, MKI67, CCNI ELANE 910/4885KDM5A 148/4885KDM5B 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.